With this many [cancer] drugs in development, I think the success rate will probably decrease.
If you define success from a commercial standpoint, your assertion is guaranteed. There are only so many reimbursement dollars available in the aggregate for all cancer drugs, so it’s mathematically impossible for more than a tiny percentage of these drug candidates to be commercially successful.
There are exceptions, of course; however, all told, cancer-drug candidates are a sucker bet, IMHO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.